Shares in United Therapeutics (NSDQ:UTHR) fell -3% yesterday on a possible delay for the release of a programmable infusion pump for its drug, Remodulin.
Yesterday, the FDA updated Medtronic‘s (NYSE:MDT) Class I recall for the company’s SynchroMed II and SynchroMed EL implantable drug pumps. RBC Capital reportedly said the recall puts United Therapeutics at heightened risk for a delay in debuting an alternative delivery option for Remodulin.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic’s SynchroMed woes delay United Therapeutic’s Remodulin appeared first on MassDevice.